Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Attilio Di Girolamo"'
Autor:
Attilio Di Girolamo, Marcello Albanesi, Alessandro Sinisi, Eustachio Nettis, Danilo Di Bona, Maria Filomena Caiaffa, Luigi Macchia
Publikováno v:
Clinical and Molecular Allergy, Vol 16, Iss 1, Pp 1-4 (2018)
Abstract Background Brentuximab vedotin (BV) is an antibody–drug conjugate formed by an anti-CD30 chimeric IgG1 conjugated with monomethyl-auristatin-E. BV targets the CD30+ cells, which characterize Hodgkin lymphoma as well as anaplastic large cel
Externí odkaz:
https://doaj.org/article/42187b0359834ee0a276ddb7d331473f
Autor:
Filomena Loconte, Luigi Macchia, Attilio Di Girolamo, Maria Filomena Caiaffa, Danilo Di Bona, Marcello Albanesi
Publikováno v:
Acta Haematologica. 143:496-499
Iron deficiency is the main cause of anemia in both sexes, with women being more commonly affected. Iron therapy is currently considered an effective and safe remedy to replenish the iron storages. Iron can be administrated both orally and intravenou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bce1440af752c77811a1a5e6ffe0799
https://doi.org/10.1159/000503768
https://doi.org/10.1159/000503768
Autor:
Vincenzo Aresta, Lucia Anna Giliberti, Maria Pia Rossi, Maria Filomena Caiaffa, Attilio Di Girolamo, Tommasina Perrone, Luigi Macchia, Marcello Albanesi, Giorgina Specchia, Danilo Di Bona
Publikováno v:
Advances in Dermatology and Allergology, Vol 35, Iss 5, Pp 527-529 (2018)
Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii
Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b66b17e5e76b8558c64347c5c6a146
https://doi.org/10.5114/ada.2018.77244
https://doi.org/10.5114/ada.2018.77244
Autor:
Luigi Macchia, Danilo Di Bona, Alessandro Sinisi, Eustachio Nettis, Marcello Albanesi, Attilio Di Girolamo, Maria Filomena Caiaffa
Publikováno v:
Clinical and Molecular Allergy : CMA
Clinical and Molecular Allergy, Vol 16, Iss 1, Pp 1-4 (2018)
Clinical and Molecular Allergy, Vol 16, Iss 1, Pp 1-4 (2018)
Background Brentuximab vedotin (BV) is an antibody–drug conjugate formed by an anti-CD30 chimeric IgG1 conjugated with monomethyl-auristatin-E. BV targets the CD30+ cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f688ea3cbad61bed2fc30e4e2a5dc989
http://europepmc.org/articles/PMC6205792
http://europepmc.org/articles/PMC6205792